Has Jacqueline Wayman received payments from drug or device companies?

Yes. Drug and device makers reported $2,505 in general payments to Jacqueline Wayman across 128 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jacqueline Wayman did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jacqueline Wayman come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jacqueline Wayman

Psychiatric/Mental Health · Omaha, NENPI 1093394843

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 35.1% of the total. Reporting peaked in 2022 at $1,199 and has fallen 81.2% since, to $225 in 2025.

$2,505in general payments, 2019–2025

Across 128 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$880
Sunovion Pharmaceuticals Inc.$411
Alkermes, Inc.$210
Lundbeck LLC$203
Otsuka America Pharmaceutical, Inc.$203
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$130
plus $468 from 13 others

What the payments were for

Food & beverage$2,505100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	46	$880
Sunovion Pharmaceuticals Inc.	21	$411
Alkermes, Inc.	6	$210
Lundbeck LLC	13	$203
Otsuka America Pharmaceutical, Inc.	11	$203
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	6	$130
Johnson & Johnson	4	$82
Vanda Pharmaceuticals Inc.	3	$78
Supernus Pharmaceuticals, Inc.	4	$66
Takeda Pharmaceuticals U.S.A., Inc.	3	$58
Harmony Biosciences LLC	2	$39
Merck	2	$27
Teva Pharmaceuticals USA, Inc.	1	$20
Axsome Therapeutics, Inc.	1	$19
E.r. Squibb & Sons, L.L.C.	1	$19
Almatica Pharma LLC	1	$17
Neos Therapeutics, LP	1	$15
Adlon Therapeutics L.p.	1	$14
Ironshore Pharmaceuticals Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LYBALVI$499
VRAYLAR$357

How this compares

$2,505 in reported general payments places this provider in the 70th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Diazepam	12	$97

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Omaha

Janelle HillOmaha$24K
Kristi BoseOmaha$13K
Robert LundholmOmaha$12K
Virginia SmithOmaha$11K
Christina HadleyOmaha$11K
Julie ZulkoskyOmaha$8K
John RamseyOmaha$8K
M Joyce SasseOmaha$7K
Molly PetersenOmaha$6K
Salina AndersonOmaha$6K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →